Cognitive-Enhancement Insurance Discrimination In Russia.
1. Introduction
Cognitive-Enhancement Insurance Discrimination in Russia concerns the legal problems arising when insurance companies treat individuals differently because they use, seek, or refuse cognitive-enhancement technologies.
Cognitive enhancement refers to interventions intended to improve or modify human cognitive abilities, including:
Neurotechnology and brain-computer interfaces (BCIs).
Prescription medicines used to improve attention, memory, or concentration.
Neural implants and cognitive-assistance devices.
Experimental brain stimulation and neurostimulation.
Genetic technologies intended to influence cognitive functions.
AI-supported cognitive enhancement and memory-assistance systems.
The central legal question is whether an insurer can increase premiums, refuse coverage, exclude particular treatments, or classify a person as high-risk because that person uses cognitive-enhancement technology.
Important legal distinction: Russia does not have a clearly established, separate statutory category called cognitive-enhancement insurance discrimination. The issue must therefore be examined through existing constitutional, civil, insurance, medical, disability, and personal-data legislation.
The analysis below distinguishes actual Russian legal provisions and judicial decisions from hypothetical disputes involving emerging neurotechnology.
2. Constitutional Framework
The Constitution of the Russian Federation provides the foundation for protecting individuals against arbitrary discrimination in insurance relationships.
Article 19 – Equality before the law
Article 19 establishes equality before the law and courts and prohibits discrimination on grounds including sex, race, nationality, language, origin, property status, official status, place of residence, religion, beliefs, and other circumstances.
Its relevance includes situations in which insurers differentiate between customers based on their medical history, disability, or use of cognitive-enhancement technology.
An insurer should be able to demonstrate a legitimate, legally defensible basis for risk classification rather than relying on stereotypes about people using neurotechnology.
Article 21 – Human dignity
Human dignity is protected by the Constitution. Insurance practices that stigmatise individuals because they have undergone neurological treatment or use cognitive-assistance devices may raise dignity-related concerns.
Article 23 – Privacy
This provision protects privacy and personal and family secrets. Neural information, medical histories, and cognitive-function assessments can raise serious privacy concerns.
Article 24 – Personal information
Article 24 restricts the collection, storage, use, and dissemination of information about a person's private life without the legally required consent or other legal basis.
Article 41 – Right to health protection and medical care
This provision protects the right to health protection and medical assistance. It is relevant where insurance exclusions interfere with access to medically necessary neurological treatment.
These constitutional provisions should be read alongside applicable federal legislation rather than treated as creating an automatic entitlement to every cognitive-enhancement treatment.
3. Russian Insurance Legislation
A. Law No. 4015-1 of 27 November 1992 – Organisation of Insurance Business
This legislation regulates insurance activities and the relationship between insurers, policyholders, and other participants in the insurance market.
It is relevant to cognitive-enhancement discrimination in three ways:
Insurance companies must operate within the statutory regulatory framework.
Insurance products and risk classifications must comply with applicable insurance standards.
Insurance decisions must respect consumer-protection requirements and applicable rules against discrimination.
B. Civil Code of the Russian Federation
The following provisions are particularly important:
| Provision | Legal significance |
|---|---|
| Article 10 | Prohibition of abuse of civil rights |
| Article 421 | Freedom of contract |
| Article 426 | Public contract requirements |
| Article 927 | Voluntary and compulsory insurance |
| Article 934 | Personal insurance contracts |
| Article 944 | Disclosure of material circumstances |
| Article 945 | Insurer's right to assess insured risk |
| Article 946 | Insurance secrecy |
Article 944 – Disclosure of material circumstances
This provision is especially important when an insurance applicant uses cognitive-enhancement medication, neurotechnology, or an experimental neurological intervention.
An insurer may ask relevant questions concerning circumstances that are material to assessing the probability of an insured event.
However, the existence of a cognitive-enhancement device or a genetic predisposition does not automatically establish that the applicant has concealed a material illness.
The precise questions asked, the applicant's knowledge, the materiality of the information, and the statutory requirements for the consequences of nondisclosure must be examined.
Article 945 – Assessment of insured risk
This provision allows an insurer, when concluding certain insurance contracts, to inspect the insured property and examine the actual condition of the insured person, subject to applicable legal restrictions.
In a hypothetical neurotechnology insurance dispute, an insurer might seek to assess:
Whether an implanted neurological device creates a medical risk.
Whether a cognitive-enhancement treatment has recognised complications.
Whether an intervention increases the probability of a particular insured event.
Whether an applicant has an existing diagnosed neurological condition.
Risk assessment must not become an arbitrary mechanism for excluding people simply because they have different cognitive characteristics.
Article 946 – Insurance secrecy
Insurance-related information is subject to legal confidentiality requirements. This is relevant where insurance companies collect sensitive neurological, medical, or cognitive information.
The insurer's access to such information does not create unrestricted permission to disclose or reuse it.
rospatent.gov.ru+1
4. Federal Law No. 152-FZ of 27 July 2006 – Personal Data Protection
This legislation is important because cognitive-enhancement technologies can generate highly sensitive information.
Examples include:
Brainwave measurements.
Memory-performance records.
Neurological assessments.
Genetic and genomic information.
Cognitive-performance scores.
Medical information generated by neural implants.
Article 5 – Principles of personal-data processing
Personal-data processing must comply with principles of lawful purpose, relevance, and proportionality.
Article 6 – Conditions for processing
Personal data may be processed only where a legally recognised basis exists.
Article 10 – Special categories of personal data
Information concerning health and other specially protected personal characteristics is subject to additional restrictions.
Article 21 – Obligations following unlawful processing
This provision establishes obligations relating to the termination or correction of unlawful personal-data processing.
For example, if an insurance company unlawfully uses neural-performance records to classify an applicant as medically dangerous, the applicant may have grounds to challenge the processing and seek applicable legal remedies.
5. Federal Law No. 323-FZ of 21 November 2011 – Protection of Health
This law regulates healthcare relationships and the rights of patients.
Article 13 – Medical confidentiality
Medical information is protected by confidentiality requirements, subject to statutory exceptions.
Article 19 – Patient rights
Patients have rights relating to medical assistance, information, and respect for their rights in healthcare relationships.
Article 20 – Informed voluntary consent
Medical interventions generally require informed voluntary consent, subject to legally specified exceptions.
These provisions become relevant when an insurance company attempts to obtain information about a person's cognitive-enhancement treatment without an appropriate legal basis.
6. The Most Important Insurance Anti-Discrimination Standard
A particularly significant authority is the Bank of Russia's Basic Standard for the Protection of Rights and Interests of Recipients of Financial Services Provided by Insurance Organisations.
Its clause 3.2.3 expressly prohibits discrimination against recipients of insurance services on specified grounds and other circumstances when concluding insurance contracts.
It also recognises an important distinction:
Determining the terms of an individual insurance contract according to the degree of risk does not, by itself, constitute discrimination.
This distinction is central to cognitive-enhancement insurance disputes.
For example:
Charging a different premium because a particular implanted device has a demonstrated, evidence-based complication risk may constitute legitimate risk assessment.
Rejecting every applicant who uses a cognitive-enhancement device without considering individual circumstances may raise discrimination concerns.
Treating experimental cognitive enhancement as proof of mental illness without medical evidence may create legal problems.
Using unlawfully obtained brain data to calculate premiums may violate personal-data protections.
The standard therefore requires a distinction between legitimate actuarial differentiation and prohibited discrimination.
sogaz.ru
7. Important Case Laws and Judicial Decisions
There is an important limitation: no verified Russian judgment identified here directly decides whether an insurer may discriminate against someone specifically for using cognitive-enhancement technology. The following cases provide relevant legal principles by analogy.
Case 1. Kiyutin v. Russia (2011)
Court: European Court of Human Rights.
Application No.: 2700/10.
Judgment date: 10 March 2011.
Legal provisions: Articles 8 and 14 of the European Convention on Human Rights.
Facts:
The Russian authorities refused a residence permit to an Uzbek national because he was HIV-positive.
Legal issue:
Whether different treatment based on health status constituted unlawful discrimination.
Judgment:
The Court found a violation of Article 14 in conjunction with Article 8. It emphasised the need for objective justification and individual assessment rather than generalised assumptions about health status.
Relevance:
An insurer assessing a cognitive-enhancement user should not automatically assume that the individual has a neurological disorder or presents an unacceptable risk merely because of the technology used.
HUDOC+1
Legal qualification: This was a residence-permit case, not an insurance dispute. It is a useful human-rights analogy, not a direct insurance precedent.
Case 2. Supreme Court of the Russian Federation – Determination No. 89-КГ24-15-К7 (29 April 2025)
Direct insurance-law authority
Court: Supreme Court of the Russian Federation.
Parties: Efimova and Malyshkina v. Insurance Company Soglasie.
Facts:
The dispute concerned a COVID-19 insurance policy. Following the insured person's death, the insurer refused payment because the deceased had accompanying medical conditions excluded under the insurance terms.
Legal issue:
Whether the insurer could rely on medical exclusions when the relevant circumstances had not been properly established as having been disclosed or asked about at the time of contracting.
Judicial reasoning:
The Supreme Court found that the lower courts had committed significant errors and overturned their decisions.
The Court considered the importance of examining whether the insurer had actually requested the relevant medical information and whether the insured person had concealed or provided false information.
Relevance:
This decision is particularly important for cognitive-enhancement insurance.
An insurer should not automatically rely on the existence of a neurological condition, implant, or medical record without examining the contractual questions, disclosure requirements, and applicable insurance provisions.
legalacts.ru+2
Case 3. Supreme Court of the Russian Federation – Review of Judicial Practice in Voluntary Personal Insurance (5 June 2019)
Subject: Voluntary personal insurance associated with consumer credit.
Legal principle:
The Supreme Court examined the consequences of knowingly providing false information about health when entering into a personal insurance contract.
Relevance:
A cognitive-enhancement applicant may be required to answer relevant health questions accurately.
However, possession of an experimental technology or an unconfirmed neurological prediction is not automatically equivalent to knowingly concealing a diagnosed illness.
The actual wording of the insurer's questions and the requirements of Article 944 of the Civil Code are important.
Case 4. Russian Constitutional Court – Judgment No. 4-П (31 January 2025)
Subject: Compensation for healthcare expenses under Article 1085 of the Civil Code.
Legal issue:
Whether reasonable and justified expenses for paid medical treatment could be reimbursed where the injured person could also have received treatment through compulsory medical insurance.
Decision:
The Constitutional Court found that Article 1085 was constitutional and did not provide grounds for refusing reasonable and justified expenses in the circumstances examined.
Relevance:
The judgment illustrates the importance of examining actual medical necessity and the justification for healthcare expenditure.
In a future dispute involving cognitive-enhancement treatment, the distinction between medically justified intervention and elective enhancement could become important.
KSRF
8. Practical Examples of Cognitive-Enhancement Insurance Discrimination
Neuralink planira proizvodnju "velikog broja" implanta za mozak - Glas Srpske
Example 1: Neural implant discrimination
An insurer refuses life insurance to an applicant simply because the applicant uses a brain-computer interface.
Legal issue: Whether the refusal is supported by an individualised and legitimate risk assessment.
ЭЭГ головного мозга или МРТ что лучше
Example 2: Cognitive-risk profiling
An insurer uses neurological test results to classify an applicant as having a high probability of future cognitive impairment.
Legal issue: Accuracy, lawful processing, medical confidentiality, and justification of the risk classification.
Los medicamentos más vendidos de este 2025
Example 3: Cognitive-enhancement medication
A person taking prescribed medication for concentration is charged a substantially higher premium.
Legal issue: Whether the premium reflects a demonstrable insurance risk or an unjustified assumption about the person's health.
AI Based Predictive Analytics Transforming Healthcare Outcomes in 2024
Example 4: AI-based insurance discrimination
An insurer uses an AI system to reject applicants based on predicted cognitive-performance scores.
Legal issue: Personal-data legality, transparency, accuracy, and the possibility of challenging an unfair decision.
These are hypothetical examples, not reported Russian court cases.
9. Legal Remedies Available to Affected Individuals
An individual who believes that an insurer has unlawfully discriminated against them may consider the following remedies.
| Institution | Possible legal action |
|---|---|
| Insurance company | Request written reasons for refusal or premium calculation |
| Bank of Russia | Submit a complaint concerning insurance practices |
| Roskomnadzor | Complain about unlawful personal-data processing |
| Civil courts | Challenge contractual decisions and seek appropriate compensation |
| Consumer-protection authorities | Raise applicable consumer-rights violations |
| Prosecutor's Office | Report violations within its supervisory competence |
Potential claims may include:
Recognition of unlawful contractual conduct.
Enforcement of contractual insurance obligations.
Compensation for legally established losses.
Protection against unlawful processing of personal data.
Compensation for moral harm where the applicable legal requirements are satisfied.
The precise remedy depends on the insurance product, contractual terms, evidence, and applicable statutory provisions.
10. Major Legal Challenges
A. Distinguishing treatment from enhancement
Russian law must address the distinction between medically necessary neurological treatment and elective cognitive enhancement.
B. Algorithmic underwriting
AI systems may classify people according to cognitive scores without adequately explaining the medical or actuarial basis of their decisions.
C. Genetic and neurological information
Insurers may obtain information that predicts a possible future condition without establishing that the individual currently suffers from that condition.
D. Unequal access to insurance
Individuals using expensive cognitive-enhancement technologies could receive different insurance treatment because of the characteristics or perceived risks of those technologies.
E. Privacy and consent
The collection of brainwave data and medical information raises questions about lawful processing, confidentiality, and appropriate consent.
11. Suggestions for Future Legal Reform in Russia
A specialised regulatory framework could introduce:
Prohibition of unjustified discrimination based on cognitive characteristics.
Evidence-based standards for neurotechnology-related insurance risk.
Restrictions on the use of genetic predictions as substitutes for medical diagnoses.
Transparency requirements for AI-based underwriting.
Independent review of automated insurance refusals.
Stronger protection of neural and cognitive information.
Individual assessment before rejecting an insurance application.
Clear procedures for challenging discriminatory premiums and exclusions.
12. Conclusion
Cognitive-Enhancement Insurance Discrimination in Russia is an emerging legal issue at the intersection of insurance regulation, constitutional equality, neuroscience, biotechnology, AI governance, and personal-data protection.
The most important legal authorities include:
Article 19 of the Russian Constitution – Equality.
Article 23 – Privacy.
Federal Law No. 4015-1 – Insurance regulation.
Civil Code Articles 944–946 – Disclosure, risk assessment, and insurance secrecy.
Federal Law No. 152-FZ – Personal-data protection.
Federal Law No. 323-FZ – Healthcare rights and medical confidentiality.
Bank of Russia Insurance Consumer Protection Basic Standard, clause 3.2.3 – Prohibition of discrimination and legitimate risk-based differentiation.
Kiyutin v. Russia (2011) – Health-status discrimination.
Supreme Court Determination No. 89-КГ24-15-К7 (2025) – Medical disclosure and insurance exclusions.
Final legal proposition: An insurance company should be able to distinguish between a genuine, evidence-based insurance risk and an unsupported assumption about an individual's cognitive characteristics. The use of cognitive-enhancement technology should not, by itself, be treated as proof of illness or as automatic justification for refusing insurance.
Research note: The cited judicial authorities provide constitutional and insurance-law analogies. They do not establish a separate Russian judicial doctrine specifically governing cognitive-enhancement insurance discrimination.

comments